You are here
Articles on Gastrointestinal Cancer
A selection of peer-reviewed articles on Gastrointestinal Cancer. All content available on the Advances in Gastrointestinal Cancer Resource Center, including original and review articles, interviews, guidelines and congress highlights, is independently selected by the members of the Editorial Board.
Low Preoperative Prognostic Nutritional Index Predicts Poor Survival Post-gastrectomy in Elderly Patients with Gastric Cancer
Sakurai K, Tamura T, Toyokawa T, Amano R, Kubo N, Tanaka H, et al.Ann Surg Oncol. 2016 May 20. [Epub ahead of print]
A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer
Nakayama N, Ishido K, Chin K, Nishimura K, Azuma M, Matsusaka S, et al.Gastric Cancer. 2016 May 17. [Epub ahead of print]
Treatment outcomes of hepatectomy for liver metastases of gastric cancer diagnosed using contrast-enhanced magnetic resonance imaging
Tatsubayashi T, Tanizawa Y, Miki Y, Tokunaga M, Bando E, Kawamura T, et al.Gastric Cancer. 2016 May 7. [Epub ahead of print]
Uhlik MT, Liu J, Falcon BL, Iyer S, Stewart J, Celikkaya H, et al.Cancer Res. 2016 May 1;76(9):2573-86.
High-risk and low-risk gastric cancer areas in Italy and its association with microsatellite instability
Polom K, Marrelli D, Pascale V, Roviello G, Voglino C, Rho H, et al.J Cancer Res Clin Oncol. 2016 May 20. [Epub ahead of print]
Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?
Chia CS, You B, Decullier E, Vaudoyer D, Lorimier G, Abboud K, et al.Ann Surg Oncol. 2016 Jun;23(6):1971-9.
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al.Lancet Oncol. 2016 May 3. [Epub ahead of print]
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial
Tebbutt NC, Price TJ, Ferraro DA, Wong N, Veillard AS, Hall M, et alBr J Cancer. 2016 Mar 1;114(5):505-9
Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study
Meulendijks D, de Groot JW, Los M, Boers JE, Beerepoot LV, Polee MB, et alCancer. 2016 May 1;122(9):1434-43.